A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post
surgery recurrence.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang University
Collaborators:
First Hospital of Jilin University Huashan Hospital Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shulan (Hangzhou) Hospital The First Affiliated Hospital of Zhengzhou University The First Hospital of Jilin University Third Affiliated Hospital, Sun Yat-Sen University Tianjin First Central Hospital West China Hospital